ClinicaSpace.com
Clinical Research
News & Careers
 
Search the Site
    
 
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login           Employers:  Register | Login   

By Industry | By Industry Segment | By Services and Suppliers | By Location | Profile Search
 Company Profile

 

Amicus Therapeutics, Inc. 

1 Cedar Brook Drive

Cranbury  New Jersey  08512  U.S.A.
Phone: 609-662-2000 Fax: 609-662-2001


SEARCH JOBS

Amicus Therapeutics is a biopharmaceutical company at the forefront of developing therapies for rare and orphan diseases. The Company is developing novel, first-in-class, small molecules called pharmacological chaperones, to treat human genetic diseases, including lysosomal storage diseases. The Company’s lead pharmacological chaperone migalastat HCl is in Phase 3 as a monotherapy for Fabry disease. Amicus and its partner GlaxoSmithKline Plc (GSK) are conducting Phase 3 registration studies of migalastat HCl for the treatment of Fabry disease. A Phase 3 study intended to support approval of migalastat HCl in the United States is fully enrolled and results are anticipated in the third quarter of 2012. Additionally, Amicus and GSK are currently conducting a separate Phase 3 study intended to further support global registration of migalastat HCl.

Amicus continues to advance its program evaluating the use of pharmacological chaperones in combination with enzyme replacement therapy (ERT) as an expansion of the chaperone technology platform. Two chaperone-ERT combinations, migalastat HCl co-administered with ERT for Fabry disease and AT2220 (duvoglustat HCl) co-administered with ERT for Pompe disease, are currently in Phase 2 development. The Company is also investigating chaperone-ERT combinations for Gaucher disease in preclinical studies.

Amicus also has a preclinical pipeline of pharmacological chaperones for diseases of neurodegeneration, including AT3375 for Parkinson’s disease. The Company has broad, issued intellectual property around the methods, use, and composition of pharmacological chaperones to treat genetic diseases and diseases of neurodegeneration. In addition to the currently issued patents, Amicus has several patent applications pending.


 Key Statistics


Email: info@amicusrx.com
Ownership: Public

Web Site: Amicus Therapeutics, Inc.
Employees: 100
Symbol: FOLD
 









 Company News
Amicus Therapeutics, Inc. (FOLD) Announces Closing Of Underwritten Offering Of Common Stock And Full Exercise Of Over-Allotment Option 11/24/2014 2:55:43 PM
Amicus Therapeutics, Inc. (FOLD) Announces Public Offering Of Common Stock 11/19/2014 4:16:22 PM
Amicus Therapeutics, Inc. (FOLD) Prices Underwritten Offering Of Common Stock 11/19/2014 12:40:32 PM
Amicus Therapeutics, Inc. (FOLD) Announces Positive Phase 3 Data On Cardiac And Composite Endpoints From Fabry Monotherapy Study 012 At American Society of Nephrology 11/17/2014 10:33:52 AM
Amicus Therapeutics, Inc. (FOLD) Announces Timing Of Third Quarter 2014 Financial Results, Upcoming Scientific Conference And Other Corporate Updates 11/3/2014 8:47:42 AM
Amicus Therapeutics, Inc. (FOLD) Announces Additional Positive Phase 3 Data From Fabry Monotherapy Study 011 10/20/2014 6:21:15 AM
Amicus Therapeutics, Inc. (FOLD) To Present At Leerink Partners Rare Disease Roundtable 9/30/2014 8:29:15 AM
Amicus Therapeutics, Inc. (FOLD) Rockets On Positive Phase 3 Study Data For Rare Disease Drug 8/20/2014 5:57:00 AM
Standing On A Ledge Once Again, Amicus Therapeutics, Inc. (FOLD) Holds Breath For Latest Study 8/11/2014 6:52:49 AM
Amicus Therapeutics, Inc. (FOLD) Announces Second Quarter 2014 Financial Results And Corporate Updates 8/8/2014 7:32:43 AM
12345678910...